SCOHIA PHARMA, Inc.
SCOHIA PHARMA, Inc.
Business
2020.05.28
Pipeline Information has been updated.
Business
2019.12.09
SCOHIA initiates a Phase1 study of a GPR40 full agonist (SCO-267)
Business
2019.11.28
SCOHIA initiates a phase 2 proof of concept study of an enteropeptidase inhibitor (SCO-792) in type 2 diabetes mellitus patients with obesity
Business
2019.11.25
SCOHIA and SEEDSUPPLY Announce Research Collaboration Agreement
Page Top